Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NNC9204-0043
- Development stage
- Preclinical
- Lead developer
- Novo Nordisk
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
NNC9204-0043 is a long-acting glucagon receptor agonist developed by Novo Nordisk. It is primarily investigated for its metabolic effects in the treatment of obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). As a glucagon receptor agonist, it promotes hepatic lipid metabolism, leading to a reduction in hepatic triglycerides and an increase in hepatic glycogen content. In preclinical models, it has been shown to enhance weight loss and improve liver health, particularly when used in combination with GLP-1 receptor agonists, by addressing hepatic steatosis through mechanisms independent of weight loss alone.
- Other names
- long-acting stable glucagon analog
02
Targets
GCGR (Glucagon receptor)
Beyond the preview
Go deeper on NNC9204-0043.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NNC9204-0043.